Human cytomegalovirus isolates were analyzed, both by restriction fragment-length polymorphism typing and by sequencing for intra-and intergenic variability at 9 sites on the genome, to determine whether genetic variation influenced disease outcome and whether linkage among genes could be identified. The effect of cytomegalovirus (CMV) strain variation on the biologic properties of the virus is a topic of current interest. Each clinical CMV isolate has the potential for a unique identity [1, 2] , which leads to the hypothesis that strain variation affects the outcome of CMV infection. Interest in strain variation has been fueled by advances such as the analysis of the complete sequence of the CMV laboratory strain AD169 [3] and sequenced-based restriction endonuclease technology that allows the identification of gene strain variants 
The effect of cytomegalovirus (CMV) strain variation on the biologic properties of the virus is a topic of current interest. Each clinical CMV isolate has the potential for a unique identity [1, 2] , which leads to the hypothesis that strain variation affects the outcome of CMV infection. Interest in strain variation has been fueled by advances such as the analysis of the complete sequence of the CMV laboratory strain AD169 [3] and sequenced-based restriction endonuclease technology that allows the identification of gene strain variants by simple restriction fragment-length polymorphism (RFLP) analysis.
The relationship between genetic variants of the envelope glycoprotein genes and disease outcome has been the focus of many studies, because these variants are major targets for virus-neutralizing antibody [4] and are essential for some functions, such as binding to receptors and cell fusion [5] . The UL55 (gB) and UL75 (gH) genes have been well studied. There are 4 major genotypes of the gB gene, distinguished by variability at the cleavage site between aa 460 and 461 of the 169-kDa gB polyprotein [6, 7] . There is also significant variability at the N terminus and limited, but predictable, variability at the C terminus [8] [9] [10] . There are 2 major variants of the gH gene, distinguished by variability at the N terminus [11] . gH is a component of the gCIII glycoprotein complex [12] , which also includes UL74 (gO) and UL115 (gL) [13, 14] . Although the function of the assembled gCIII complex is unknown, gL is necessary for the transport of gH from the nuclear membrane to the cell surface [15, 16] , and gO has been associated with fusion of CMV-infected cells [17, 18] . Phylogenetic groups that can be identified by RFLP patterns enable relatively simple surveys of the distribution of gO and gL gene variants in different patient populations [19] . CMV pathogenesis may involve interactions of multiple genes. To gain insight into whether the use of multiple genetic markers would be useful in predicting the outcome of CMV infection, we studied the genetic variation in the nonglycoprotein US9 and US28 genes. Our goal was to determine whether linkages existed from the US9 and US28 genes to variants of the envelope gB gene and the genes encoding the gCIII complex of gH, gL, and gO. We chose the US9 and US28 genes because they have biologic activities that are distinct from those associated with viral glycoproteins. The US9 gene may be a determinant of replication and dissemination in polarized epithelial cells derived from human retina [20, 21] . The US28 gene codes for a functional CC chemokine receptor [22] [23] [24] that can promote smooth-muscle cell migration in the presence of CC chemokines.
The full-length sequence of the US9 and US28 genes, the sequence of the C-terminal region of the gB gene, and restriction endonuclease analysis based on known sequence variation in the genes encoding the gCIII complex and the N terminus and cleavage site of the gB gene were used to analyze the distribution of the variants of each of these genes in patient populations at risk for CMV infection or reactivation.
SUBJECTS, MATERIALS, AND METHODS
Viruses. Blood buffy coats, urine, and bronchoalveolar lavage samples were obtained from immunosuppressed patients, some positive and some negative for human immunodeficiency virus (HIV). Both commercially obtained MRC5 and locally prepared human lung fibroblast cells were used for all CMV cultures. Clinical isolates had been passaged !5 times before storage at Ϫ70ЊC. Laboratory strains AD169, Towne, and Toledo had an unknown passage history, but for this study, they were cultured in human fibroblast cultures.
Study cohort. In addition to the 3 laboratory CMV strains, a total of 87 isolates from 77 patients were used in this study. Isolates were from HIV-positive patients ( ), allograft ren p 37 cipients ( ), and congenitally CMV-infected infants n p 36 ( ). Genetic data for all of the 9 genomic sites was available n p 4 for 13 of the 87 isolates. The criteria for including selected subpopulations are described in each experimental section.
Sequence analysis. The US9 and US28 genes and the C terminus of the gB gene were analyzed by sequencing. The fulllength US9 gene was 744 nt long, and the full-length US28 gene was 1065 nt long. Proteinase K-digested samples were amplified by polymerase chain reaction (PCR), using primers specific for the C terminus of the gB gene and the US9 and US28 genes, as shown in table 1. Samples were diluted 1:10-1: 100 to give a final volume of 100 mL of a master mix-sample solution. All master mixes contained 1ϫ PCR buffer, 2.5 mM MgCl 2 , 150 mM each dNTP, 2.5 U of Taq polymerase (Life Technologies), and 20 pmol each of upper and lower primers (Operon Technologies). Cycling parameters were 95ЊC for 30 s; 40 cycles of 94ЊC for 15 s, 55ЊC for 20 s, and 70ЊC for 2 min; and a final 10-min hold at 72ЊC.
After amplification of the full-length gene was done, PCR products were purified (QIAquick PCR purification kit; Qiagen) and typically diluted to a concentration of 100 ng for sequencing. For sequencing reactions, 10 mL of each sample was used, with dRhodamine dye-labeled dideoxyterminators (Applied Biosystems) and 5 pmol of each of the corresponding sequencing primers. The sequencing reactions were then analyzed on an ABI Model 377 instrument (Applied Biosystems). Data were assembled manually, proofread, and edited using ABI sequence analysis software (Applied Biosystems). Nucleotide and amino acid deviations were determined by comparison with the AD169 consensus sequence. Multiple sequencings of laboratory strains and patient samples were performed to val-idate the reproducibility of the sequence determination, as well as to rule out laboratory contamination.
Phylogenetic analysis. DNA sequences of the US9 and US28 genes were aligned and analyzed using PAUP version 3.0 software (Sinauer Associates) [25] for analysis of relationships by the generation of phylogenetic trees. The radially described phylogenetic trees were constructed using neighbor-joining methods with a maximum-likelihood-based distance. For each gene, a single, unrooted tree with 100 bootstrap values was generated. Bootstrap values of у60% were used to define nodes of the phylogenetic trees. The description of the phylogenetic analysis of the gO and gL genes has been published elsewhere [19] .
RFLP analysis of gene variants. To distinguish between the full-length (long) form and the truncated (short) form of the US9 gene, a 997-bp fragment was amplified, using primers shown in table 1. The purified amplification product was diluted to a final concentration of ∼200 ng in a 20-mL reaction mixture of the appropriate restriction endonuclease buffer and 1 mL (10,000 U) of Bsu36I enzyme (New England Biolabs). The reaction products were incubated for 2 h at 37ЊC and analyzed in 3% ethidium bromide-stained Metaphor agarose gels (FMC BioProducts).
The N-terminal variants of the gB gene were characterized using a series of restriction enzyme digests. A 450-bp region of the N terminus between bases Ϫ6 and 444 was amplified using primers gBNi5 and gBNi3 [10] . The resulting 450-bp PCR product was digested with 3 individual restriction enzymes, BstNI, HpaI, and TaqaI, and the products were analyzed using electrophoresis in 3% Metaphor Tris-boric acid-EDTAbuffered agarose gels.
The C-terminal variants of the gB gene were analyzed by sequencing of a 506-bp region of the gB gene between bases 2032 and 2537. The 5 primers were as described elsewhere [10] , but for 3 amplification of the C terminus, primer gB2Ci3 was used (table 1) .
Restriction-based methods for identifying the 4 gB cleavage site and 2 gH gene variants have been published elsewhere [26] , as have the methods for identifying the genes encoding the gCIII complex [19] . We were unable to develop a reliable restriction-based method for identifying the US9 and US28 genes and the C terminus of the gB gene. Therefore, these variants were classified by sequence analysis only.
Statistical analysis. A x 2 test with Yates's correction was used for comparisons of differences between groups of samples.
RESULTS
Phylogenetic assessment of the relationship between intragenic variants for the US9 and US28 genes. Phylogenetic trees based on the sequences for the US9 and US28 genes are shown in figure 1. Only sequences with no evidence of mixtures in the sequencing chromatograms were analyzed for phylogenetic relationships. The accession numbers submitted to GenBank are AY174238-AY174263 for the US9 gene sequences and AY174264-AY174288 for the US28 gene sequences. Twenty-six isolates were analyzed for the US9 gene; 3 were laboratory strains, and the others were from a cohort of 13 allograft recipients, 6 HIV-positive patients, and 4 congenitally CMV-infected infants. For the US9 gene (figure 1A), 4 major nodes were identified. The short form of US9, observed exclusively in phylogenetic group 3, was defined by a 35-nt deletion between bases 691 and 724 of the full-length 744-bp gene. This results in a frame shift to a TAA stop codon at position 732, followed by the deletion of an additional 10 bases of the original gene that occur after the TAA stop codon. Laboratory strains Towne and Toledo, as well as 2 of 6 of the clinical isolates in group 3, had the US9 short form genotype. A single isolate, v8000, could not be classified into a well-defined group and was designated "ungroupable" (figure 1A).
Isolates from 25 patients were analyzed for the US28 gene sequence. Three laboratory strains and isolates from a cohort of 12 allograft recipients, 6 HIV-positive patients, and 4 congenitally CMV-infected infants were used. There was overlap with most of the strains sequenced for the US9 gene. Four major nodes were identified for the US28 gene (figure 1B) with significant bootstrap values 160% [25] . Variants in groups 1, 2, and 3 were diffuse but could be grouped. In contrast, group 4 isolates fell into a tightly clustered group that branched from the same node as the more highly dispersed group 1 variants.
Only epidemiologically related strains had total sequence identity. Two isolates from the same individual, isolated from culture within a 1-month period, had identical sequences, as did isolates from twin infants born with congenital CMV infection (data not shown). Patient groups were randomly distributed among phylogenetic groups for the US9 and US28 gene sequences.
Variability in the US9 and US28 genes was estimated by comparison of nucleotide and amino acid sequences with those of laboratory strain AD169. The US9 and US28 gene sequences were highly conserved, showing a maximum divergence from the AD169 sequence of 3.3% for the US9 gene and 1.8% for the US28 gene at both the nucleotide and the amino acid level.
The US9 gene length was examined after a single digest of the 997-bp PCR product at the C terminus of the gene with Bsu36I (figure 2). The long and short variants could easily be distinguished by RFLP analysis (figure 2). There was perfect correlation of sequence and restriction endonuclease data for the 26 samples studied by both sequencing and RFLP methods (21 long and 5 short forms).
Intragenic variability at the cleavage sites and N and C termini among variants 1, 2, 3, and 4 in the gB gene. Based on the N-terminal sequence variation data obtained from Gen- Figure 1 . Phylogenetic relationships of intragenic variants of the US9 (A) and US28 (B) genes are shown in unrooted radial trees. The radial trees were constructed using neighbor-joining methods with a maximum-likelihood-based distance. For each gene, a single, unrooted tree with 100 bootstrap values was generated. The bootstrap values, estimating frequency of relatedness, are shown at the junction of the major nodes. The individual groups represent clinical isolates derived from both allograft recipients and human immunodeficiency virus-infected patients, and the individual isolates are designated by a combination of letters and numbers that are unlinked to any patient identity records. In A, isolate v8000 is designated "ungroupable" (UG), because it did not fall into any of the obvious genetic groups for the US9 gene. The short forms are shown in italic type. Laboratory strains AD169, Towne, and Toledo are shown for both the US9 and the US28 gene and are designated by name.
Bank, a computer-based restriction enzyme digestion scheme was devised. Theoretical digestion patterns were generated for the 4 major and 2 minor variants of the N terminus of the gB gene, as originally described by Meyer-Konig et al. [10] . The gBNi5 and gBNi3 primers described by Meyer-Konig et al. [10] were then used to amplify a 450-bp fragment of the gB gene N terminus between positions Ϫ6 and 444, using the AD169 sequence as a reference. Digestion of the resulting fragment with 3 separate restriction digests using TaqaI, BstNI, and HpaI gave characteristic patterns for each of the gB N-terminal genetic variants that were consistent with the patterns predicted by the computer model. The gB N-terminal variants 1-6 could be clearly identified by comparing the RFLP results of each digest (figure 3).
The gB genes from a subpopulation of 45 clinical isolates drawn from the total group of 87 isolates available for study and 3 laboratory strains were analyzed for intragenic variability. All data are from individual patients; patients with mixtures at any gB region were excluded from the analysis. The patient population consisted of 16 patients with HIV, 26 allograft recipients, and 3 infants with congenital CMV infection. Data for all 3 regions of the gB gene were required for inclusion in the analysis. The gB variants were first grouped according to cleavage site variation, followed by tabulation of the number of prototypic versus nonprototypic isolates for both the N and the C terminus (table 2). Prototypes are the N-or C-terminal variants that match numerically with the cleavage variants (e.g., gB-cls1, -N1, and -C1/2), according to the scheme proposed by Meyer-Konig et al. [10] . The gB C-terminal variant designation "1/2" indicates a match with either gB-cls1 or gB-cls2. The C-terminal variant designation "3/4" indicates a match with either gB-cls3 or gB-cls4. gB-cls1, -cls3, and -cls4 showed a high degree of matching with prototypic N-terminal variants. However, gB-cls2 appeared to be associated with nonprototypic N-terminal variants more frequently than were the other cleavage site variants ( ; x 2 analysis with Yates's correction). P ! .05 gB-cls4 showed a higher percentage of variability at the C terminus than did the other cleavage site variants, but the small number of isolates with gB-cls4 detected in this study precluded statistical analysis.
Analysis of intragenic linkages among the CMV genes. Three laboratory strains and 13 clinical isolates were free of mixtures and were analyzed at all 9 sites used in this study. The 13 clinical isolates were drawn from the total population of 87 isolates included in the study pool and represent data from single patients (2 HIV-positive individuals, 2 congenitally CMV-infected infants, and 9 allograft recipients) (table 3). The data in table 3 are grouped first by the gB cleavage site variant, because this is a widely used basis for characterizing clinical isolates. Although there was identity at some loci for clinical isolates and laboratory strains, particularly at the gB loci, there were usually differences at other genomic sites. In this study, there was not a single isolate that was identical at all 9 sites to any of the laboratory strains.
To determine whether it would be possible, by using a larger cohort, to identify linkages between pairs of genotypes, data from 35 clinical isolates and the 3 laboratory strains were analyzed on a pairwise basis. The group of 35 isolates was selected from the total population of 87 clinical isolates. The basis for selection was the availability of genotype data for a minimum of 6 of the 9 sites studied and the absence of evidence of mixtures at any of the sites for which data were available. Each of the isolates is from a single donor. The data are not matched longitudinally, because technical limitations, such as presence of inhibitors or insufficient sample, prevented gene amplification of some samples. The number of different variant groups that were detected in association with a single genotype (indicated in the left column of table 4) was then scored for each gene variant (shown at the top of table 4). For example, 2 of the 4 possible gB cleavage site variants were detected in association with gB-N1. Similarly, 3 of the 4 gO variants were detected in association with gB-N1. Reading the 9 genomic sites defined in this study across table 3 shows that the number of possible combinations of gene variants is remarkably high. For example, when only the existing genotypes for the gB N terminus and gB cleavage site pairs are used as a basis for calculation, there are at least 256 possible combinations.
Data were arranged in a tabular configuration that allowed pairwise comparison on a numerical variant-to-variant basis (data not shown). For example, tables comparing the 2 ϫ 2 frequency of a single genotype (A) in association with a different unrelated genotype (B) with the frequency of A in all of the other unrelated genotype groups (e.g., C and D) were analyzed by x 2 testing with Yates's correction. Only previously reported linkages that were statistically significant ( ) were found, P ! .05 and these are shown in table 4. For example, within a group of 8 isolates with gB-cls1, all 8 had gB-N1 and gB-C1/2 (P ! ; x 2 test with Yates's correction), whereas gB-N1 was much .05 less common among isolates with gB-cls2, -cls3, or -cls4, as has been reported elsewhere [10] . Similarly, the associations of the 2 C-terminal variants with prototypic cleavage site variants were significant. A significant association ( ; x 2 test with P ! .05 Yates's correction) between gO-1 and gH-1 variants has also been reported elsewhere [19] ; of 10 isolates with gO-1, 9 also had gH-1, and only 1 isolate with gH-1 did not have gO-1. No significant association with the gH variation was found for the gO-2, -3, and -4 genotypes [19] .
Analysis of isolates that are homogeneous at a single site for mixtures at other loci. The data shown in table 5 were derived from the entire group of 87 isolates from 77 patients. Isolates that were found to be homogeneous either by RFLP analysis or at a single genomic site were analyzed pairwise for the presence of identifiable mixtures at other sites (table 5) . The number of isolates for which genotype data were available that allowed an analysis of mixtures at any single site is shown in table 5. Many isolates that had only a single genotype at one location revealed mixtures at other genomic sites. The gB Nterminal and cleavage site variants were most likely, on a percentage basis, to contribute to mixtures of variants. The frequency of mixtures in conjunction with detection of only a single gene was high for the gO and US9 genes. gH gene variants were uniformly homogeneous in isolates with no evidence of mixtures. Some mixing of gL gene variants was observed, but the frequency was !10% among isolates that had homogeneity at a single site.
The lack of reliable RFLP techniques limited the analysis of mixtures for US28 and US9 genotypes. Because all US9 short forms were US9-3, the existence of the US9 short form in association with US9-1, -2, or -4 indicated the presence of mixtures and provided a minimum estimate of US9 mixture frequency. One-way analysis for the presence of mixtures occurring in conjunction with the US28 gene was possible and showed that unmixed US28 genotypes could also be mixed at other sites on the viral genome. However, the frequency of US28 mixtures was not compared to that of other genotypes, because we did not feel that chromatographic methods were sufficiently reliable, on a sample-to-sample basis, to consistently detect mixtures. Distribution of genotypes according to HIV serostatus or site of isolation. The distribution of the genotypes was evaluated in a subpopulation of 68 isolates from the 77-patient cohort. Isolates were divided into those from HIV-positive ( ) and those from HIV-negative ( ) subjects. Ison p 31 n p 37 lates with mixtures were excluded from the analysis. Only the genotype data for the first sample were used for analysis of samples from the 6 patients who were monitored prospectively. Nineteen isolates from HIV-positive subjects were analyzed for gB N-terminal variants, 30 for gB cleavage site variants, 28 for gB C-terminal variants, 17 for gO variants, 31 for gH variants, 4 for US9 variants, and 4 for US28 variants. Thirty isolates 2  7  2  3  1  2  3  2  2  3  9  3  3  2  2  3  2  3   4  6  3  3  2  2  3  1  2  gH, FLS   1  1 8  4  4  2  4  4  3  3  2  1 5  3  4  2  3  3  2  1   gL, FLS   1  2  2  2  1  2  1  1  1  2  4  3  3  2  3  2  2  2   3  9  3  3  2  4  2  3  2   4  1 8  3  4  2  4  2  3  3  US9, FLS   1  6  2  3  2  2  2  4  4   2   h   0  0  0  0  0  0  0  0   3  3  2  2  1  2  1  2  1   4  4  3  4  2  3  2  2  3  US28, FLS  1  3  3  3  1  2  2  3  1   2  4  4  3  1  4  2  3  2  3  4  1  2  2  3  2  2  2  4  3  2  2  2  2  2  2  3 NOTE. Of the total pool of 87 isolates, 35 were selected for which there was an absence of detectable mixtures and for which data were available for at least 6 of the 9 genomic sites studied. Linkages in boldface were statistically significant ( 
NOTE.
Isolates were drawn for analysis from the total pool of 87 isolates from 77 immunocompromised patients described in Subjects, Materials, and Methods. Sequential analysis was available for 6 of 77 patients. From the 6 serially observed patients, 10 samples in which a mixture of new genotypes, compared with any of the previous samples, was detected were included in the analysis. C, C terminus; cls, cleavage site; N, N terminus; n/N, no. of isolates with mixtures/no. examined for mixtures. Isolates examined for mixtures were those for which data were available from the total population of isolates that were homogeneous at a single site.
a Variability within the first 148 aa of the N terminus of the 55-kDa gB cleavage product. b Variability surrounding the cleavage site on the 160-kDa gB polyprotein between aa 460 and 461. c Variability within the last 169 aa of the C terminus of the 160-kDa uncleaved gB polyprotein.
from HIV-negative subjects were analyzed for gB N-terminal variants, 37 for gB cleavage site variants, 37 for gB C-terminal variants, 30 for gO variants, 37 for gH variants, 13 for US9 variants, and 14 for US28 variants. When the data were grouped to evaluate distribution of genotypes, only gB-N2 and gB-cls2 were distributed differently among isolates from HIV-negative patients and those from HIV-positive patients. There were 5 gB-N2 isolates among those from 18 HIV-positive patients that were tested and 19 gB-cls2 isolates among those from 30 HIVpositive patients, compared with 1 gB-N2 isolate among those from 30 allograft recipients and 9 gB-cls2 isolates among those from 37 allograft recipients. The significance of these differences in distribution between HIV-positive and HIV-negative patients is (x 2 test with Yates's correction). The higher prevalence P ! .05 of gB-N2 among isolates from HIV-positive patients reflects its linkage to gB-cls2 and the high incidence of gB-cls2 isolates in the HIV-positive patient population that has been reported elsewhere [27] . The gB-N5 and -N6 genotypes [10] were detected in only 6 isolates from the total group of 87.
Isolates from various specimens that had no evidence of mixtures of strains also were analyzed to seek distribution patterns related to the site of isolation (40 isolates from blood, 14 from urine, and 15 from tissue samples). Tissue samples included various samples from bronchoalveolar lavage, throat swabs, and vitreous humor of HIV-positive patients with CMV retinitis. No correlations between genotype and site of isolation were detected (data not shown).
Conservation of virus strains during longitudinal analysis of isolates from the same patient. Five HIV-positive patients were monitored longitudinally for periods ranging from 2 to 12 months. In 4 of these 5 patients, the gB genotype first detected was generally conserved, but new gB variants for all variant regions of the gB gene were readily detected. However, such conservation of genotype was not the case for the gO, gH, and UL115 genes. Replacement of one genotype by a different one was observed in 4 of 5 patients for both the gO and the gH gene and in 2 of 5 patients for the gL gene.
DISCUSSION
This study has provided a preliminary basis for understanding the well-recognized strain variability that results in a unique identity for all epidemiologically unrelated viruses. The major findings of our study are that (1) on the basis of an analysis of only 9 genomic sites, it is apparent that an almost infinite number of genetic combinations are theoretically possible; (2) genetic linkages are rare; (3) intragenic variability may add a further complicating factor to molecular epidemiologic studies; (4) analysis of only a single gene from a clinical isolate may not reflect the presence of either intragenic variants or mixtures of genotypes. It has been suspected that CMV genetic variation plays a role in the ability of CMV infection to manifest itself in so many different organ systems. However, the clinical condition of an infected human is a poor indicator of virulence, because CMV frequently is shed in the absence of symptomatic disease.
Most recently, epidemiologic studies have focused on the importance of variation in the glycoprotein genes as a factor in the clinical outcome of CMV infection. However, the conclusions of studies seeking an association of gB genotype with the outcome of CMV infection are inconsistent . The demographic characteristics of infected individuals may explain some of the discrepancies. For example, the reported association of gB-cls2 with retinitis may be related to a high prevalence of gB-cls2 among homosexual patients with AIDS [27] . In addition, the intragenic variability of the gB gene [10] has not been considered in most of the cited studies and could play a role in the molecular epidemiology of the gene.
The data in the present study lead to the conclusion that study of a single gene is inadequate for investigating the molecular epidemiology of CMV. First, changes at one genetic locus do not necessarily reflect changes at other sites. Some genetic linkages have been reported for CMV, but they do not appear to be sufficient to predict variability throughout the genome. For example, gB-cls2 and gB-cls4 occur frequently in isolates with gH-1 [34] , and the gO-1 genotype appears to be linked to the gH-1 genotype in the genes encoding the gCIII complex [19] . However most of the published studies report only limited linkages, particularly when nonglycoprotein genes are compared with the gB gene [50] . In addition to the absence of consistent genetic linkages, a significant number of isolates show mixtures at sites other than that of the single gene being studied. Future studies would benefit from the use of methods that will sensitively detect such mixtures or from the choice of genes with highly variable sequences to facilitate detection of mixed infections.
The degree of conservation among CMV genes is variable. In this study, we report that the US9 and US28 genes have !4% variability, compared with the predicted amino acid sequence. In a previous study [19] , we showed that the gL gene is highly conserved, whereas gO genotypic variants can differ by as much as 50%. The UL54 open-reading frame (ORF) that codes for DNA polymerase also appears to be highly conserved, with !2% variability among clinical isolates [51] . The gB and gH genes show somewhat more variability among clinical isolates, with differences at the amino acid level approaching 15% [7, 11] . There are 3 phylogenetic groups of the UL144 ORF that encodes a homologue of the tumor necrosis factor receptor, and variability is as high as 21% among the variant groups [52] . The nucleotide variability within 4 phylogenetically defined variant groups of the UL4 ORF can be as high as 23% [50] . The UL11 ORF also shows a high level of intragenic variability, on the order of у40% (based on data from 10 clinical isolates) [53] . The UL73 (gN) ORF, which codes for an envelope glycoprotein that is a target for virus-neutralizing antibody, is also reported to be associated with 4 highly divergent genotypes [54] .
The impact of the differences in variability at the genetic level on the biology of the virus is unknown.
The use of RFLP analysis in our study to identify genotypes may lead to underestimation of the true number of sequence variants. RFLP analysis detects only a limited number of variant nucleotides specific to the recognition site of the restriction enzyme. Strain variation may be even more extensive than is indicated by RFLP analysis. Evidence showing that the distance differences among strains are different within most of the major nodes of the phylogenetic trees supports the idea that RFLP analysis may not reflect the total sequence variability among strains.
The inter-and intragenic variability in CMV clinical isolates emphasizes the likely futility of using sequence information alone to predict disease outcome. One may speculate that the phenotype of the isolate may be even more important than the sequence variability. The study of phenotypes of drug-resistant variants of HIV in association with sequence analysis underscores the importance of understanding the biology of the virus for prediction of the outcome of HIV infection. In the HIV model, sequence mutations in drug-resistant variants will not necessarily correlate with drug-resistance phenotypes [55] . New methods of identifying CMV phenotypes may be necessary if we are to improve our understanding of the relevance of strain variability to disease outcome. One approach may be to analyze the ability of CMV isolates to replicate in highly specialized cells, rather than the standard human fibroblasts that are used routinely for virus culture. In vitro models of specialized cells have been proposed as a means of differentiating CMV strains [45, [56] [57] [58] [59] [60] [61] , but no definitive system has emerged that is useful for cataloging CMV isolates. The conflicting reports with regard to the role of the US9 gene in cell-to-cell spread [21, 62] might be resolved by an examination of the sequences of the genes used in each of the studies. Strain-specific differences in the origin of replication of CMV have also been reported [63] . Each of the cited systems has potential for identifying phenotypic variants of CMV. Systematic efforts to identify phenotypic variants for replication in vitro in cells that may reflect in vivo viral tropisms may be warranted.
The genetic variation of CMV becomes increasingly important as efforts to develop a CMV vaccine gain momentum [64, 65] . The action of NK cells has been reported to be dependent on virus strain [66] . Strain-specific epitopes are associated with virus-neutralizing antibody [67] [68] [69] . Preexisting immunity to one strain of CMV will not necessarily be protective against reinfection with a novel strain of the virus [9, [70] [71] [72] [73] . This concept is reinforced by our data from HIV-positive patients, which show reinfection or reactivation with completely different genotypes for all of the genomic sites evaluated in this study. Current efforts to develop a CMV vaccine [65, 74] should consider the differences in the genetic structure of laboratory strains and clinical isolates to be a potential problem area for achieving protective immunity against all variants of CMV. Efforts should be made to include highly conserved genes that may be more likely to provide broad-spectrum immunity than are genes that show extensive variation.
